Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

- Significant clinical progress noted in small cell lung, prostate and

colorectal cancer trials -

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today provided an update of its picoplatin development program in small cell lung cancer (SCLC), colorectal cancer (CRC) and hormone refractory prostate cancer (HRPC), and its oral formulation in solid tumors. Presenting at the Lazard Capital Markets Healthcare Conference in New York, Jerry McMahon, Ph.D., chairman and CEO of Poniard, noted that the Company has made significant progress in 2007 in its clinical development program for picoplatin, its lead product candidate.

"2007 has been an important year for Poniard, as we have continued to advance our development of picoplatin, a new generation chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations," said Dr. McMahon. "We continue to drive our clinical programs toward completion and have achieved significant milestones this year. In addition, we remain on track to file our NDA for picoplatin in 2009."

Poniard is providing an update on the progress on all four of its picoplatin clinical trials, as follows:

Phase 3 SPEAR Trial:

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

To date
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Northstar Global Business ... after months of hard work from many talented ... Snorenz formulation and package design.  The new formulation ... back into the product due to overwhelming evidence ... effects.  Snorenz Nighttime will also include these vitamins, ...
(Date:8/20/2014)... 2014  The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful PSE sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 32,105 boxes of ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... , The US FDA announced on August 15, that ... Solution with 2.5% Dextrose 5000mL (Ambu-Flex II), by Baxter ... presence of particulate matter. , The reason for ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... Washington Crossing, PA (PRWEB) August 21, 2014 ... at Washington Crossing Historic Park in Washington Crossing, Pennsylvania ... to maintain the park. “We have been looking for ... community organizations,” said Matt Kiernan, Partner with Pharmica Consulting. ... a significant part of U.S. history, we jumped at ...
(Date:8/21/2014)... 2014 The Rottenstein Law Group LLP, ... years of experience advocating for plaintiffs with claims of ... devices, announces the launch of its new website, ... believe they have been harmed by prescription drugs or ... the severe adverse side effects suffered by women allegedly ...
(Date:8/21/2014)... She was 12 years old when the unthinkable happened ... to correct her frequent headaches failed. , In her ... shares her journey of overcoming devastating obstacles involving dual disability, ... of justice for years. , “My faith in God ... the light,” Strom-Stewart said. “But it took me more than ...
Breaking Medicine News(10 mins):Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2
... at Online Radiology Medical Group, Inc. is pleased to announce new ... and functional MRI consulting and reading services. , ... ... -- Jesse Salen, the VP of Sales and Technology at ...
... metabolism booster, weight reducer and athletic enhancer, sales of acai products have ... in the Brazilian rainforest from acai palms that may reach heights in ... harvest edible hearts of palm. , ... Green Bay, WI (PRWEB) November ...
... which young people livefamilies, peers, schools, and neighborhoodscontribute both ... risk from one area possibly being magnified or decreased ... a new longitudinal study conducted by researchers at the ... of California at Davis, and the University of California ...
... little to other diagnostic measures, British researchers report , , ... (EKG) -- the standard test for measuring the activity ... predicting future coronary problems for people who are examined ... "In patients with stable chest pain, suspected angina, the ...
... 13, 2008 James G.,Carlson, Chairman and CEO of AMERIGROUP ... Birth Report Card," which was,released November 12 by the March ... fair chance to grow up in good,health. But as the ... Report Card, that is not the case today. Studies show ...
... There are more than 70,million Americans over the ... part,of Kmart,s effort to provide helpful information about growing ... November 18th from 9am-1pm,at all 1100 Kmart pharmacy locations., ... blood pressure,screenings, free memory screenings, Medicare health plan selection,assistance ...
Cached Medicine News:Health News:New Teleradiology Reading Services Are Available at Online Radiology Medical Group, Inc. 2Health News:New Teleradiology Reading Services Are Available at Online Radiology Medical Group, Inc. 3Health News:Research Finds The Brazilian Acai Absorbs Much Better Than Any Other Fruit 2Health News:Families, friends, schools and neighborhoods contribute to adolescent alcohol misuse 2Health News:EKG Not Strong Predictor of Heart Risk 2Health News:EKG Not Strong Predictor of Heart Risk 3Health News:AMERIGROUP Chairman and CEO Urges Action to Improve Nation's 'Premature Birth Report Card' 2Health News:Kmart Pharmacy Celebrates GoldK Day for Seniors 2
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv1000, HME...
Ballard trach care HMES and filters, tv 500, HME...
Indications For Usage:, ,Single use on tracheostomy patients who can breathe spontaneously. The product is intended to be replaced at least once every 24 hours....
Medicine Products: